Multicenter cohort study of the effect of Crinone® progesterone vaginal gel alone to prepare the endometrium for frozen–thawed blastocyst transfer in a hormone replacement cycle
Journal of Obstetrics and Gynaecology Research · 2025
DOI: 10.1111/jog.16325 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Akiko Takashima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Toho University Medical Center Sakura Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Progesterone, Embryo Transfer, Endometrium, Vaginal Creams, Foams, and Jellies. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Biopharma Co., Ltd.
Abstract (Originalsprache)
Aim
Progesterone has to be administered to prepare the endometrium for frozen–thawed blastocyst transfer (FBT) in a hormone replacement cycle (HRC). The objective of this study was to investigate the efficacy and safety of using Crinone® progesterone gel alone in HRC‐FBT.
Methods
In this multicenter prospective study, HRC‐FBT was performed with blastocysts with a Gardner's classification of 3BB or better, and application of 90 mg/day of vaginal gel (Crinone, Merck BioPharma, Tokyo) was started when the endometrial thickness reached 8 mm or more. The primary endpoint was the clinical pregnancy rate (CPR). Safety endpoints included genital bleeding and other adverse events. Recruitment started in May 2018.
Results
A total of 181 patients were enrolled, and 156 were included in the efficacy analysis. The overall CPR was 41.7% (65/156). In patients younger than 38 years ( n = 113), the CPR was 48.7% (55/113), and in those aged 38 years or older ( n = 43), it was 23.3% (10/43). The overall CPR was comparable to that observed in the Japan Society of Obstetrics and Gynecology ART2020 National Survey, which reported a pregnancy rate of 36.3% in frozen embryo transfer cycles. Adverse events such as light genital bleeding occurred before and after pregnancy in some patients, but at a low frequency (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Toho University Medical Center Sakura Hospital, Chiba, Japan.
- Cinema Art Clinic, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
- Nishitan ART clinic Shinagawa, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Nippon Medical School, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga, Japan.
ORCID-Profile: Akiko Takashima, Yoshimitsu Kuwabara, Fuminori Kimura
Förderung
- Merck Biopharma Co., Ltd
Zitieren
APA
Takashima, A., Shibui, Y., Hamatani, T., Suenaga, A., Kuwabara, Y., Kimura, F., Nakagawa, K., Fukuda, Y., Tokunaga, S., & Katagiri, Y. (2025). Multicenter cohort study of the effect of Crinone® progesterone vaginal gel alone to prepare the endometrium for frozen–thawed blastocyst transfer in a hormone replacement cycle. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16325
Vancouver
Takashima A, Shibui Y, Hamatani T, Suenaga A, Kuwabara Y, Kimura F, et al. Multicenter cohort study of the effect of Crinone® progesterone vaginal gel alone to prepare the endometrium for frozen–thawed blastocyst transfer in a hormone replacement cycle. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16325
BibTeX
@article{Takashima2025,
author = {Takashima, Akiko and Shibui, Yukihiro and Hamatani, Toshio and Suenaga, Akihiko and Kuwabara, Yoshimitsu and Kimura, Fuminori and Nakagawa, Koji and Fukuda, Yusuke and Tokunaga, Shoji and Katagiri, Yukiko},
title = {Multicenter cohort study of the effect of Crinone® progesterone vaginal gel alone to prepare the endometrium for frozen–thawed blastocyst transfer in a hormone replacement cycle},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
doi = {10.1111/jog.16325}
}
EUVIMED